These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35934678)

  • 21. Airway autoimmunity, asthma exacerbations, and response to biologics.
    Venegas Garrido C; Mukherjee M; Bhalla A; Nair P
    Clin Exp Allergy; 2022 Dec; 52(12):1365-1378. PubMed ID: 35993511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions.
    Oppenheimer J; Hoyte FCL; Phipatanakul W; Silver J; Howarth P; Lugogo NL
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):169-180. PubMed ID: 35272048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
    Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
    Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
    Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
    Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Therapeutic Potential of Targeting Cytokine Alarmins to Treat Allergic Airway Inflammation.
    Sy CB; Siracusa MC
    Front Physiol; 2016; 7():214. PubMed ID: 27378934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.
    Chen CY; Wu KH; Guo BC; Lin WY; Chang YJ; Wei CW; Lin MJ; Wu HP
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-alarmin approaches entering clinical trials.
    Gauvreau GM; White L; Davis BE
    Curr Opin Pulm Med; 2020 Jan; 26(1):69-76. PubMed ID: 31408015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex association patterns for inflammatory mediators in induced sputum from subjects with asthma.
    Hastie AT; Steele C; Dunaway CW; Moore WC; Rector BM; Ampleford E; Li H; Denlinger LC; Jarjour N; Meyers DA; Bleecker ER;
    Clin Exp Allergy; 2018 Jul; 48(7):787-797. PubMed ID: 29520864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype.
    Moermans C; Damas K; Guiot J; Njock MS; Corhay JL; Henket M; Schleich F; Louis R
    Cytokine; 2021 Apr; 140():155421. PubMed ID: 33486314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation.
    Busse WW; Kraft M; Rabe KF; Deniz Y; Rowe PJ; Ruddy M; Castro M
    Eur Respir J; 2021 Aug; 58(2):. PubMed ID: 33542055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased expression of upstream TH2-cytokines in a mouse model of viral-induced asthma exacerbation.
    Mahmutovic Persson I; Akbarshahi H; Menzel M; Brandelius A; Uller L
    J Transl Med; 2016 Feb; 14():52. PubMed ID: 26879906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients.
    Truyen E; Coteur L; Dilissen E; Overbergh L; Dupont LJ; Ceuppens JL; Bullens DM
    Thorax; 2006 Mar; 61(3):202-8. PubMed ID: 16449261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
    Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.
    Hamada K; Oishi K; Murata Y; Hirano T; Matsunaga K
    J Asthma Allergy; 2021; 14():1463-1471. PubMed ID: 34908847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts.
    Hoshino Y; Soma T; Uchida Y; Shiko Y; Nakagome K; Nagata M
    Front Pharmacol; 2022; 13():836635. PubMed ID: 35517829
    [No Abstract]   [Full Text] [Related]  

  • 38. T2 Biologics for Chronic Obstructive Pulmonary Disease.
    Yousuf A; Ibrahim W; Greening NJ; Brightling CE
    J Allergy Clin Immunol Pract; 2019; 7(5):1405-1416. PubMed ID: 31076058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in asthma biomarker research.
    Leung TF; Ko FW; Wong GW
    Ther Adv Respir Dis; 2013 Oct; 7(5):297-308. PubMed ID: 23907809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.